Perspectives in Clinical Research, 2021 Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer.
Prabhat Agrawal +5 more
doaj +1 more source
Toxicology Reports, 2016 Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In
Yuzuru Iizuka +5 more
doaj +1 more source
Pioglitazone Prevents Capillary Rarefaction in Streptozotocin-Diabetic Rats Independently of Glucose Control and Vascular Endothelial Growth Factor Expression [PDF]
, 2012 Background/Aims: Reduction of capillary network density occurs early in the development of metabolic syndrome and may be relevant for the precipitation of diabetes.
Andreas Dendorfer +42 more
core +1 more source
RPB4 and pathogenesis of diabetes [PDF]
, 2007 Obesity is an important risk factor for a number of chronic diseases that impose a huge burden on individuals and society. Recently it has become clear that adipose tissue-secreted products may play a significant role in mediating many obesity-related ...
Kumar, Sudhesh +1 more
core +1 more source
Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study. [PDF]
, 2016 We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression.
Blackburn, E +4 more
core +1 more source
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]
, 2017 RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K +7 more
core +2 more sources
The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users [PDF]
, 2016 Aims: Activation of PPARγ by pioglitazone (PIO) has shown some efficacy in attenuating addictive-like responses in laboratory animals. The ability of PIO to alter the effects of opioids in humans has not been characterized in a controlled laboratory ...
Alonzo +74 more
core +1 more source
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +10 more sources
Cardiovascular Diabetology, 2020 Background Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare.
Yi-Chih Hung +3 more
doaj +1 more source
Short-term therapy with rosiglitatzone, a PPAR-¿ agonist improves metabolic profile and vascular function in non-obese lean wistar rats [PDF]
, 2012 A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic subjects and animal models of diabetes.
Abubakari, Abdul-Razak +3 more
core +1 more source